The Lancet

Development and validation of peripheral blood DNA methylation signatures to predict response to biological therapy in adults with Crohn's disease (EPIC-CD): an epigenome-wide ...

aDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands bTytgat Institute for Liver and Intestinal Research, Amsterdam ...
The Lancet

Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trials

aDivision of Gastroenterology & Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AL, Canada bDepartment of Community Health Sciences, University of ...

Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study

Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Buy and Hold For the Next 3 Years. On February 19, Eli Lilly and Company (NYSE:LLY) released positive results from the Phase 3 VIVID-2 ...